CClinicalTrials.gg
Status unknownNCT03282786CO2-IBDUpdated Jun 16, 2020

Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease

An interventional study of carbon dioxide insufflation during colonoscopy in Inflammatory Bowel Diseases, sponsored by University Hospital Muenster. Status unknown at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by University Hospital Muenster · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients with inflammatory bowel disease (IBD) frequently undergo endoscopic examination and may suffer from diagnostic procedures. Independent from IBD patients, colonoscopy is usually performed using air insufflation, however recent data indicates a superior role of carbon dioxide (CO2) as an insufflation gas during colonoscopy. Using CO2 leads to a lower degree of patient's discomfort. The role of CO2 as an insufflation gas for colonoscopy in IBD patients remains undetermined, wherefore this study aims to address this issue.

Read the detailed description

Patients with inflammatory bowel disease (IBD) suffer from a chronic inflammatory course of disease. To stage the course of disease endoscopic procedures including colonoscopy may be required and especially IBD patients with their inflamed gut may suffer from repetitive endoscopic examinations including colonoscopy. Independent from IBD patients, colonoscopy is usually performed using air insufflation, however recent data indicates a superior role of carbon dioxide (CO2) as an insufflation gas during colonoscopy. Using CO2 leads to a lower degree of patient's discomfort which has been mainly demonstrated in groups of patients undergoing cancer surveillance colonoscopies and who do not suffer from IBD. Therefore the role of CO2 as an insufflation gas for colonoscopy in IBD patients remains undetermined and this study aims to address this issue. For pain assessment a visual analogue scale will be used. As the primary outcome measure, the investigators will compare the differences in pain level 1h after colonoscopy (comparison of carbon dioxide to air insufflation). For the secondary outcome measure the investigators will compare the differences in pain level 3h, 6h and 24h after colonoscopy (comparison of carbon dioxide to air insufflation).

02

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • Inflammatory Bowel Disease
  • Crohn's Disease
  • Ulcerative Colitis
  • Carbon Dioxide (CO2)
  • Colonoscopy
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient with inflammatory bowel disease
  • Indication for colonoscopy
  • Age 18-80 years
  • signed consent form

Exclusion criteria

Exclusion Criteria:

  • Consent form not signed
  • Age \< 18 or above 80 yrs
  • Pregnancy or Breast-Feeding
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
304 participants (estimated)

Study arms

  • Active comparator
    CD patient with CO2 insufflation

    The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.

    Other: carbon dioxide insufflation during colonoscopy

  • No intervention
    CD patient with air insufflation

    The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.

  • Active comparator
    UC patient with CO2 insufflation

    The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.

    Other: carbon dioxide insufflation during colonoscopy

  • No intervention
    UC patient with air insufflation

    The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.

Interventions

  • Othercarbon dioxide insufflation during colonoscopy

    Use of Carbon dioxide instead of air insufflation

05

What researchers measure

Primary outcomes

  1. Comparison of colonoscopy related abdominal pain 1 hour after examination assessed by a visual analogue pain scale in patients with inflammatory bowel disease

    For pain assessment a visual analogue scale will be used. For the primary outcome measure, the investigators will compare the difference in pain level 1 hour after colonoscopy (comparison of carbon dioxide to air insufflation).

    Time frame: Pain level assessment 1 hour after colonoscopy

Secondary outcomes

  1. Comparison of colonoscopy related abdominal pain 3 hours, 6 hours and 24 hours after examination assessed by a visual analogue pain scale in patients with inflammatory bowel disease

    For pain assessment a visual analogue scale will be used. For the secondary outcome measure, the investigators will compare the differences in pain level 3 hours, 6 hours and 24 hours after colonoscopy (comparison of carbon dioxide to air insufflation).

    Time frame: Pain level assessment 3 hours, 6 hours and 24 hours colonoscopy

06

Study locations

1 of 1 sites recruiting
  • Unversity Clinic Muenster
    Muenster, NRW 48149, Germany
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03282786
Lead sponsor
University Hospital Muenster
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Sep 3, 2017
Primary completion
Aug 1, 2021 (estimated)
Completion
Jan 31, 2022 (estimated)
Last update
Jun 16, 2020

Study contacts

Frank Lenze, MD
Contact
frank.lenze@uni-muenster.de
0049-251-8358103
Arne Bokemeyer, MD
Contact
arne.bokemeyer@ukmuenster.de
0049-251-8347661
Frank Lenze, MD
principal investigator · Department of Medicine B, University Hospital Muenster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion